PF-Atlas › Clinical Trials › NCT03540524
A Study Looking at the Safety, Tolerability and Efficacy of the Combination of the Study Drugs GLPG2451 and GLPG2222 With or Without GLPG2737 in Patients With Cystic Fibrosis.
GLPG2451 dose regimen A · Phase 1
Registry ID
NCT03540524
Phase
Phase 1
Status
Completed
Drug / intervention
GLPG2451 dose regimen A
Sponsor
Lakefront Biotherapeutics NV
Start
2018-05-31
Enrollment
10
Locations
20
About this trial
This is a Phase Ib, multi-center, open-label, nonrandomized multiple cohorts study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of a combination treatment of GLPG2451 and GLPG2222, with and without GLPG2737, in adult subjects with Cystic Fibrosis.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03540524 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.